A PET-compatible tissue bioreactor for research, discovery, and validation of imaging biomarkers and radiopharmaceuticals: System design and proof-of-concept studies

Journal of Nuclear Medicine

Volumn 54, Issue 10, 2013, Pages 1812-1819

  Whitehead, Timothy D ^a   Nemanich, Samuel T ^a   Dence, Carmen ^a   Shoghi, Kooresh I ^a,b,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY IN ST LOUIS   (United States)

^c WASHINGTON UNIVERSITY   (United States)

Author keywords

Biomarker discovery; Bioreactor; Imaging; Positron emission tomography (PET); Tissue engineering

Indexed keywords

BIOLOGICAL MARKER; DISSOLVED OXYGEN; GLUCOSE; LIPID; PALMITIC ACID C 11; PIOGLITAZONE; RADIOPHARMACEUTICAL AGENT; DIAGNOSTIC AGENT; PALMITIC ACID DERIVATIVE;

ARTICLE; BIOREACTOR; CELL CHAMBER; CONTROLLED STUDY; DRUG RESEARCH; EFFLUENT; GAS EXCHANGER; GLUCOSE TRANSPORT; HEPG2 CELL LINE; HUMAN; HUMAN CELL; LABORATORY DEVICE; LIPID TRANSPORT; MECHANICAL PROBE; MOLECULAR DIAGNOSIS; OXYGEN CONSUMPTION; PERFUSION; PERISTALTIC PUMP; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TISSUE BIOREACTOR; TISSUE SPECIFICITY; VALIDATION PROCESS; BIOMARKER DISCOVERY; CELL STRAIN HEPG2; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECT; EQUIPMENT DESIGN; FEASIBILITY STUDY; IMAGING; METABOLISM; POSITRON EMISSION TOMOGRAPHY (PET); RESEARCH; TISSUE ENGINEERING; TRANSPORT AT THE CELLULAR LEVEL; DIAGNOSTIC USE; DRUG EFFECTS;

BIOMARKER DISCOVERY; BIOREACTOR; IMAGING; POSITRON EMISSION TOMOGRAPHY (PET); TISSUE ENGINEERING;

BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; BIOREACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; EQUIPMENT DESIGN; FEASIBILITY STUDIES; GLUCOSE; HEP G2 CELLS; HUMANS; LIPIDS; PALMITATES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RESEARCH;

EID: 84891669048     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.119776     Document Type: Article

References (32)

1. Guguen-Guillouzo C, Guillouzo A. Modulation of functional activities in cultured rat hepatocytes. Mol Cell Biochem. 1983;53-54:35-56.
2. Schnabel M, Marlovits S, Eckhoff G, et al. Dedifferentiation-associated changes in morphology and gene expression in primary human articular chondrocytes in cell culture. Osteoarthritis Cartilage. 2002;10:62-70.
3. 18F-FDG pet studies in mice. J Nucl Med. 2006;47:999-1006.
4. Horber FF, Krayer S, Miles J, Cryer P, Rehder K, Haymond MW. Isoflurane and whole body leucine, glucose, and fatty acid metabolism in dogs. Anesthesiology. 1990;73:82-92.
5. Lattermann R, Schricker T, Wachter U, Georgieff M, Goertz A. Understanding the mechanisms by which isoflurane modifies the hyperglycemic response to surgery. Anesth Analg. 2001;93:121-127.
6. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods. 2007;4:359-365.
7. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8:839-845.
8. Pörtner R, Nagel-Heyer S, Goepfert C, Adamietz P, Meenen NM. Bioreactor design for tissue engineering. J Biosci Bioeng. 2005;100:235-245.
9. Martin I, Wendt D, Heberer M. The role of bioreactors in tissue engineering. Trends Biotechnol. 2004;22:80-86.
10. Fiegel HC, Kaufmann PM, Bruns H, et al. Hepatic tissue engineering: from transplantation to customized cell-based liver directed therapies from the laboratory. J Cell Mol Med. 2008;12:56-66.
11. Gloster JA, Harris P. Observations on an enzymic method for the estimation of pyruvate in blood. Clin Chim Acta. 1962;7:206-211.
12. Christensen ML, Meibohm B, Capparelli EV, Velasquez-Mieyer P, Burghen GA, Tamborlane WV. Single- and multiple-dose pharmacokinetics of pioglitazone in adolescents with type 2 diabetes. J Clin Pharmacol. 2005;45:1137-1144.
13. Yki-Järvinen H. Thiazolidinediones and the liver in humans. Curr Opin Lipidol. 2009;20:477-483.
14. Dence CS, Herrero P, Schwarz SW, Mach RH, Gropler RJ, Welch MJ. Imaging myocardium enzymatic pathways with carbon-11 radiotracers. Methods Enzymol. 2004;385:286-315.
15. Glantz SA. Primer of Biostatistics. 6th ed. New York, NY: McGraw-Hill; 2005.
16. Young CD, Anderson SM. Sugar and fat -that's where it's at: metabolic changes in tumors. Breast Cancer Res. 2008;10:202-210.
17. Grommes C, Landreth GE, Heneka MT. Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists. Lancet Oncol. 2004;5:419-429.
18. He X, Esteva FJ, Ensor J, Hortobagyi GN, Lee M-H, Yeung S-CJ. Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with her2+ breast cancer. Ann Oncol. 2012;23:1771-1780.
19. He X-X, Tu SM, Lee M-H, Yeung S-CJ. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. Ann Oncol. 2011;22:2640-2645.
20. Jiang Y, Huang Y, Cheng C, et al. Combination of thiazolidinedione and hydralazine suppresses proliferation and induces apoptosis by pparg up-expression in mda-mb-231 cells. Exp Mol Pathol. 2011;91:768-774.
21. Sikka S, Chen L, Sethi G, Kumar AP. Targeting ppargamma signaling cascade for the prevention and treatment of prostate cancer. PPAR Res. 2012;2012:968040.
22. Takano S, Kubota T, Nishibori H, et al. Pioglitazone, a ligand for peroxisome proliferator-activated receptor-g acts as an inhibitor of colon cancer liver metastasis. Anticancer Res. 2008;28:3593-3599.
23. Gao D, Nong S, Huang X, et al. The effects of palmitate on hepatic insulin resistance are mediated by nadph oxidase 3-derived reactive oxygen species through jnk and p38mapk pathways. J Biol Chem. 2010;285:29965-29973.
24. Lee JY, Cho HK, Kwon YH. Palmitate induces insulin resistance without significant intracellular triglyceride accumulation in hepg2 cells. Metabolism. 2010; 59:927-934.
25. Kojima K, Shimada T, Nagareda Y, et al. Preventive effect of geniposide on metabolic disease status in spontaneously obese type 2 diabetic mice and free fatty acid-treated hepg2 cells. Biol Pharm Bull. 2011;34:1613-1618.
26. Lou T, Zhang Z, Xi Z, et al. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation. 2011;34:659-667.
27. Lei H, Lu F, Dong H, et al. Genistein reverses free fatty acid-induced insulin resistance in hepg2 hepatocytes through targeting jnk. J Huazhong Univ Sci Technolog Med Sci. 2011;31:185-189.
28. Campbell MJ, Carlberg C, Koeffler HP. A role for the ppargamma in cancer therapy. PPAR Res. 2008;2008:314974.
29. Camp JP, Capitano AT. Induction of zone-like liver function gradients in hepg2 cells by varying culture medium height. Biotechnol Prog. 2007;23:1485-1491.
30. Hu M, Polyak K. Microenvironmental regulation of cancer development. Curr Opin Genet Dev. 2008;18:27-34.
31. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet. 2009;25:30-38.
32. Park JE, Tan HS, Datta A, et al. Hypoxic tumor cell modulates its microenvironment to enhance angiogenic and metastatic potential by secretion of proteins and exosomes. Mol Cell Proteomics. 2010;9:1085-1099.